Showing 6801-6810 of 7742 results for "".
- FDA Agrees to Priority Review of Cemiplimab for Advanced Squamous Cell Carcinomahttps://practicaldermatology.com/news/fda-agrees-to-priority-review-of-cemiplimab-for-advanced-squamous-cell-carcinoma/2457785/The FDA has accepted the Biologics License Application (BLA) for cemiplimab for the treatment of patients with metastatic cutaneous squamous cell carcinoma (CSCC) or patients with locally advanced CSCC w
- Hair Products for Black Women May Contain Mix of Hazardous Ingredientshttps://practicaldermatology.com/news/hair-products-for-black-women-may-contain-mix-of-hazardous-ingredients/2457790/Black women are potentially exposed to dozens of hazardous chemicals through their hair products, finds a new report in the journal Environmental Research. The study, led by scientists at Silent Spr
- Cellulite Market Expected to Growhttps://practicaldermatology.com/news/cellulite-market-expected-to-grow/2457792/The cellulite treatment market is expected to grow worldwide, as the obesity epidemic grows. Findings are in the comprehensive research report by Future Market Insights entitled “Cellulite Treatment Market
- Marriage May Reduce Risk of Dying from Melanomahttps://practicaldermatology.com/news/marriage-may-reduce-risk-dying-from-melanoma/2457797/Married folks are more likely to spot a melanoma early, compared with individuals who were never married, divorced or widowed, a new study shows. Researchers tracked data from more tha
- Dermatologist Publishes Practice Planning Guide, "Moxie Mindset"https://practicaldermatology.com/news/dermatologist-publishes-practice-planning-guide-moxie-mindset/2457804/New York City dermatologist Dina D. Strachan, MD has published "Moxie Mindset," a book that offers "secrets of building a profitable, independent physicians practice in a competitive environment." Dr. Strachan details her personal journey to building a thriv
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E
- GlobalData: Sun Pharma's Ilumya To Face Strong Competition in the US markethttps://practicaldermatology.com/news/globaldata-sun-pharmas-ilumya-will-face-strong-competition-in-the-us-market/2457816/It’s a tough road ahead for Sun Pharma’s newly approved Ilumya, according to a new report from
- BTL to Showcase Groundbreaking Research, Latest Innovation at American Society for Laser Medicine & Surgery Annual Conferencehttps://practicaldermatology.com/news/btl-to-showcase-groundbreaking-research-latest-innovation-at-american-society-for-laser-medicine-surgery-annual-conference/2457817/BTL has had nine scientific abstracts and four ePosters accepted for presentation at the 38th Annual Conference of the American Society for Laser Medicine & Surgery (ASLMS) tak
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years
- Escalier Biosciences Closes Financing, Focuses on Psoriasishttps://practicaldermatology.com/news/escalier/2457821/Escalier Biosciences BV, a privately held biopharmaceutical company, this month closed $19 million Series B financing. The round was led by Forbion with existing investors New Science Ventures and BioGeneration Ventures (BGV) completing the round. Escalier is developing both topic